C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 27 PLN -0.18%
Market Cap: 1.5B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Celon Pharma SA
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Celon Pharma SA
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
Celon Pharma SA
WSE:CLN
Accrued Liabilities
zł29.8m
CAGR 3-Years
-1%
CAGR 5-Years
43%
CAGR 10-Years
N/A
M
Molecure SA
WSE:MOC
Accrued Liabilities
zł800.3k
CAGR 3-Years
17%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
C
Cannabis Poland SA
WSE:CBD
Accrued Liabilities
zł58.6k
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
N/A
No Stocks Found

Celon Pharma SA
Glance View

Market Cap
1.4B PLN
Industry
Pharmaceuticals

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

CLN Intrinsic Value
9.2 PLN
Overvaluation 66%
Intrinsic Value
Price
C

See Also

What is Celon Pharma SA's Accrued Liabilities?
Accrued Liabilities
29.8m PLN

Based on the financial report for Jun 30, 2024, Celon Pharma SA's Accrued Liabilities amounts to 29.8m PLN.

What is Celon Pharma SA's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
43%

Over the last year, the Accrued Liabilities growth was 1%. The average annual Accrued Liabilities growth rates for Celon Pharma SA have been -1% over the past three years , 43% over the past five years .

Back to Top